Nautilus Biotechnology reported a net loss of $14.7 million for the first quarter of 2026, a $1.9 million improvement over the $16.6 million loss recorded in the same period last year. The company’s earnings per share of –$0.12 beat the consensus estimate of –$0.17, a $0.05 or 29% upside that reflects disciplined cost management and a tighter operating budget.
Operating expenses fell 14% year‑over‑year to $16.1 million from $18.8 million in Q1 2025. The reduction was driven by lower salaries, benefits, stock‑based compensation and facility costs, underscoring the company’s focus on lean operations while it continues to invest in its platform development.
The company highlighted progress toward commercialization, noting early customer engagement that validates the value of its platform in real‑world research settings. It also advanced its broadscale capabilities, including the development of a next‑generation assay format designed to improve probe compatibility, performance and scalability. The addition of experienced sales leadership is intended to accelerate the Early Access Program and support the transition to full commercial availability.
Nautilus remains a pre‑revenue company; it does not report quarterly revenue, but it expects full‑year 2026 revenue of approximately $0.5 million, with recognition delays attributed to grant‑related timing issues. The modest revenue outlook reflects the company’s current stage of development and its focus on building a customer base rather than generating sales volume.
Sujal Patel, CEO of Nautilus Biotechnology, said, "In Q1, we made measurable progress toward commercialization, with early customer engagement reinforcing the value of our platform in real‑world research settings. We also advanced our broadscale capabilities, including development of a next‑generation assay format designed to improve probe compatibility, performance, and scalability. Together with the addition of experienced sales leadership, these efforts position us to scale Early Access and progress toward full commercial availability."
Cash, cash equivalents and investments totaled $143.4 million as of March 31 2026, providing a runway that extends through 2027 under current burn assumptions. The strong liquidity position gives the company flexibility to continue investing in platform development and market expansion while maintaining disciplined cost control.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.